Li, Yanyang; Zhou, Yan; Qian, Pengyu; Wang, Yongzhen; Jiang, Falong; Yao, Zhenglin; Hu, Wenxiang; Zhao, Yanjin; Li, Shuxin published an article in Bioorganic & Medicinal Chemistry Letters. The title of the article was 《Design, synthesis and bioevaluation of novel benzamide derivatives as HDAC inhibitors》.Recommanded Product: 78109-26-9 The author mentioned the following in the article:
A series of novel benzamide derivatives was designed and synthesized as HDAC inhibitors. Exploration of the structure-activity relationships resulted in compounds that are potent in vitro. In addition, the best compound exhibited an acceptable pharmacokinetic profile with bioavailability in rat of 81% and could be considered as a candidate compound for further development. The results came from multiple reactions, including the reaction of 1-(Imidazo[1,2-a]pyrazin-3-yl)ethanone(cas: 78109-26-9Recommanded Product: 78109-26-9)
1-(Imidazo[1,2-a]pyrazin-3-yl)ethanone(cas: 78109-26-9) is a member of imidazole. Its exclusive structural characteristics with enviable electron-rich features are favorable for imidazole-based fused heterocycles to bind efficiently with an array of enzymes and receptors in biological systems through various weak interactions like hydrogen bonds, ion-dipole, cation-π, π-π stacking, coordination, Van der Waals forces, hydrophobic effects, etc., and therefore they demonstrate widespread bioactivities. Recommanded Product: 78109-26-9